{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:34:05Z","timestamp":1793414045456,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04126-0","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T07:39:27Z","timestamp":1764574767000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of androgen deprivation therapy and novel hormonal therapy on thyroid hormone levels in prostate cancer patients: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Haidi","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,1]]},"reference":[{"key":"4126_CR1","doi-asserted-by":"publisher","first-page":"103484","DOI":"10.1016\/j.esmoop.2024.103484","volume":"9","author":"MC Cursano","year":"2024","unstructured":"Cursano MC, Valsecchi AA, Pantano F, Di Maio M, Procopio G, Berruti A, et al. Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies. ESMO Open. 2024;9:103484.","journal-title":"ESMO Open"},{"key":"4126_CR2","first-page":"729","volume":"15","author":"M Salido","year":"2000","unstructured":"Salido M, Vilches J, L\u00f3pez A. Neuropeptides bombesin and calcitonin induce resistance to etoposide induced apoptosis in prostate cancer cell line. Histol Histopathol. 2000;15:729\u201338.","journal-title":"Histol Histopathol"},{"key":"4126_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","volume":"43","author":"C Huggins","year":"1941","unstructured":"Huggins C, Stevens RE Jr, Hodges CV. Studies on prostate cancer: the effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209\u201323.","journal-title":"Arch Surg"},{"key":"4126_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/ijc.33332","volume":"148","author":"O Aksoy","year":"2021","unstructured":"Aksoy O, Pencik J, Hartenbach M, Moazzami AA, Schlederer M, Balber T, et al. Thyroid and androgen receptor signaling are antagonized by\u00b5-Crystallin in prostate cancer. Int J Cancer. 2021;148:731\u201347.","journal-title":"Int J Cancer"},{"key":"4126_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00858","volume":"9","author":"Q Feng","year":"2019","unstructured":"Feng Q, He B. Androgen receptor signaling in the development of castration-resistant prostate cancer. Front Oncol. 2019;9:858.","journal-title":"Front Oncol"},{"key":"4126_CR6","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s11606-007-0291-4","volume":"22","author":"EF Yee","year":"2007","unstructured":"Yee EF, White RE, Murata GH, Handanos C, Hoffman RM. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med. 2007;22:1305\u201310.","journal-title":"J Gen Intern Med"},{"key":"4126_CR7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/pros.24323","volume":"82","author":"JM Liu","year":"2022","unstructured":"Liu JM, Chen YT, Wu CT, Hsu WL, Hsu RJ. Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases. Prostate. 2022;82:809\u201315.","journal-title":"Prostate"},{"key":"4126_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25179245","volume":"25","author":"B Hantusch","year":"2024","unstructured":"Hantusch B, Kenner L, Stanulovi\u0107 VS, Hoogenkamp M, Brown G. Targeting androgen, thyroid hormone, and vitamin A and D receptors to treat prostate cancer. Int J Mol Sci. 2024;25:17.","journal-title":"Int J Mol Sci"},{"key":"4126_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1677\/joe.1.06786","volume":"190","author":"B Anguiano","year":"2006","unstructured":"Anguiano B, Lopez A, Delgado G, Romero C, Aceves C. Deiodinase type 1 activity is expressed in the prostate of pubescent rats and is modulated by thyroid hormones, prolactin and sex hormones. J Endocrinol. 2006;190:363\u201371.","journal-title":"J Endocrinol"},{"key":"4126_CR10","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0581","volume":"11","author":"B Anguiano","year":"2022","unstructured":"Anguiano B, de Montes Oca C, Delgado-Gonzalez E, Aceves C. Prostate gland as a target organ of thyroid hormones: advances and controversies. Endocr Connect. 2022;11:e210581.","journal-title":"Endocr Connect"},{"key":"4126_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1677\/joe.0.1320177","volume":"132","author":"R Bilek","year":"1992","unstructured":"Bilek R, Gkonos PJ, Tavianini MA, Smyth DG, Roos BA. The thyrotrophin-releasing hormone (TRH)-like peptides in rat prostate are not formed by expression of the TRH gene but are suppressed by thyroid hormone. J Endocrinol. 1992;132:177\u201384.","journal-title":"J Endocrinol"},{"key":"4126_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/(SICI)1097-0045(19980615)36:1<8::AID-PROS2>3.0.CO;2-F","volume":"36","author":"RR Mani Maran","year":"1998","unstructured":"Mani Maran RR, Subramanian S, Rajendiran G, Sunil N, Archunan G, Arunakaran J, et al. Prostate-thyroid axis: stimulatory effects of ventral prostate secretions on thyroid function. Prostate. 1998;36:8\u201313.","journal-title":"Prostate"},{"key":"4126_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0303-7207(95)03490-X","volume":"109","author":"M Esquenet","year":"1995","unstructured":"Esquenet M, Swinnen JV, Heyns W, Verhoeven G. Triiodothyronine modulates growth, secretory function and androgen receptor concentration in the prostatic carcinoma cell line LNCaP. Mol Cell Endocrinol. 1995;109:105\u201311.","journal-title":"Mol Cell Endocrinol"},{"key":"4126_CR14","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1210\/endo.140.4.6666","volume":"140","author":"S Zhang","year":"1999","unstructured":"Zhang S, Hsieh ML, Zhu W, Klee GG, Tindall DJ, Young CY. Interactive effects of triiodothyronine and androgens on prostate cell growth and gene expression. Endocrinology. 1999;140:1665\u201371.","journal-title":"Endocrinology"},{"key":"4126_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.2164\/jandrol.04162","volume":"26","author":"ML Hsieh","year":"2005","unstructured":"Hsieh ML, Juang HH. Cell growth effects of triiodothyronine and expression of thyroid hormone receptor in prostate carcinoma cells. J Androl. 2005;26:422\u20138.","journal-title":"J Androl"},{"key":"4126_CR16","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1016\/S0022-5347(05)64161-4","volume":"168","author":"S Lehrer","year":"2002","unstructured":"Lehrer S, Diamond EJ, Stone NN, Droller MJ, Stock RG. Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia. J Uroloy. 2002;168:2431\u20133.","journal-title":"J Uroloy"},{"key":"4126_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/S1078-1439(02)00210-7","volume":"21","author":"S Lehrer","year":"2003","unstructured":"Lehrer S, Diamond EJ, Stone NN, Droller MJ, Stock RG, Stone M, et al. Elevated serum triiodothyronine (t3) in Ashkenazi Jewish prostate cancer patients carrying the I1307k allele of the APC (adenopolyposis coli) gene. Urologic Oncology: Seminars and Original Investigations. 2003;21:101\u20134.","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"key":"4126_CR18","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/bjc.1997.445","volume":"76","author":"TJ Key","year":"1997","unstructured":"Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT. A case-control study of diet and prostate cancer. Br J Cancer. 1997;76:678\u201387.","journal-title":"Br J Cancer"},{"key":"4126_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215581","volume":"532","author":"C Miro","year":"2022","unstructured":"Miro C, Di Giovanni A, Murolo M, Cicatiello AG, Nappi A, Sagliocchi S, et al. Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer. Cancer Lett. 2022;532:215581.","journal-title":"Cancer Lett"},{"key":"4126_CR20","doi-asserted-by":"publisher","DOI":"10.1530\/ETJ-22-0228","volume":"12","author":"S Torabinejad","year":"2023","unstructured":"Torabinejad S, Miro C, Barone B, Imbimbo C, Crocetto F, Dentice M. The androgen-thyroid hormone crosstalk in prostate cancer and the clinical implications. Eur Thyroid J. 2023;12:e220228.","journal-title":"Eur Thyroid J"},{"key":"4126_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1530\/JOE-20-0310","volume":"247","author":"A Sanchez-Tusie","year":"2020","unstructured":"Sanchez-Tusie A, Montes de Oca C, Rodr\u00edguez-Castel\u00e1n J, Delgado-Gonz\u00e1lez E, Ortiz Z, \u00c1lvarez L, et al. A rise in T3\/T4 ratio reduces the growth of prostate tumors in a murine model. J Endocrinol. 2020;247:225\u201338.","journal-title":"J Endocrinol"},{"key":"4126_CR22","unstructured":"Wells GA, Shea B, O\u2019Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2021. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 3 May 2021."},{"key":"4126_CR23","doi-asserted-by":"crossref","unstructured":"Barker TH, Hasanoff S, Aromataris E, Stone JC, Leonardi-Bee J, Sears K et al. The revised JBI critical appraisal tool for the assessment of risk of bias for analytical cross-sectional studies. JBI Evid Synth.2025-06-10.","DOI":"10.11124\/JBIES-24-00523"},{"key":"4126_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/00001813-200404000-00007","volume":"15","author":"E Salminen","year":"2004","unstructured":"Salminen E, Koskinen A, Backman H, Nurmi M. Effect of adjuvant androgen deprivation on thyroid function tests in prostate cancer patients. Anticancer Drug. 2004;15:351\u20136.","journal-title":"Anticancer Drug"},{"key":"4126_CR25","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1097\/01.cad.0000173474.82486.74","volume":"16","author":"J Morote","year":"2005","unstructured":"Morote J, Esquena S, Orsola A, Salvador C, Trilla E, Cecchini L, et al. Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer. Anticancer Drug. 2005;16:863\u20136.","journal-title":"Anticancer Drug"},{"key":"4126_CR26","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1210\/js.2017-00057","volume":"1","author":"R Hoermann","year":"2017","unstructured":"Hoermann R, Cheung AS, Milne M, Grossmann M. Hypothalamic-Pituitary-Thyroid axis set point alterations are associated with body composition in Androgen-Deprived men. J Endocr Soc. 2017;1:874\u201385.","journal-title":"J Endocr Soc"},{"key":"4126_CR27","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1089\/thy.2024.0254","volume":"35","author":"S Jasim","year":"2025","unstructured":"Jasim S, Papaleontiou M. Considerations in the diagnosis and management of thyroid dysfunction in older adults. Thyroid. 2025;35:624\u201332.","journal-title":"Thyroid"},{"key":"4126_CR28","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.7150\/ijms.109606","volume":"22","author":"D Liu","year":"2025","unstructured":"Liu D, Fang S, Gao D, Wang Z, Wang T, Tang L, et al. Establishment of reference intervals for serum Thyroid-related hormones in the Chinese Oldest-old. Int J Med Sci. 2025;22:2408\u201318.","journal-title":"Int J Med Sci"},{"key":"4126_CR29","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","volume":"3","author":"C Fitzmaurice","year":"2017","unstructured":"Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of diseasestudy. JAMA Oncol. 2017;3:524\u201348.","journal-title":"JAMA Oncol"},{"key":"4126_CR30","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12020-023-03420-9","volume":"84","author":"J Jonklaas","year":"2024","unstructured":"Jonklaas J. Hypothyroidism, lipids, and lipidomics. Endocrine. 2024;84:293\u2013300.","journal-title":"Endocrine"},{"key":"4126_CR31","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41574-023-00911-7","volume":"20","author":"D van Heemst","year":"2024","unstructured":"van Heemst D. The ageing thyroid: implications for longevity and patient care. Nat Rev Endocrinol. 2024;20:5\u201315.","journal-title":"Nat Rev Endocrinol"},{"key":"4126_CR32","first-page":"1140","volume":"33","author":"GA Brent","year":"2023","unstructured":"Brent GA. A historical reflection on scientific advances in understanding thyroid hormone action. Thyoid. 2023;33:1140\u20139.","journal-title":"Thyoid"},{"key":"4126_CR33","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1186\/s12877-024-05643-5","volume":"24","author":"GC Uyar","year":"2024","unstructured":"Uyar GC. K\u0131 l\u0131 \u00e7 MK. Evaluation of the effects of thyroid functions on frailty in geriatric patients using the Edmonton, SOF and FRAIL scales. BMC Geriatr. 2024;24:1051.","journal-title":"BMC Geriatr"},{"key":"4126_CR34","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s12020-023-03460-1","volume":"84","author":"U Feldt-Rasmussen","year":"2024","unstructured":"Feldt-Rasmussen U, Effraimidis G, Bliddal S, Klose M. Consequences of undertreatment of hypothyroidism. Endocrine. 2024;84:301\u20138.","journal-title":"Endocrine"},{"key":"4126_CR35","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1097\/CM9.0000000000002208","volume":"135","author":"B Guan","year":"2022","unstructured":"Guan B, Luo J, Huang X, Tian F, Sun S, Ma Y, et al. Association between thyroid hormone levels and frailty in the community-dwelling oldest-old: a cross-sectional study. Chin Med J. 2022;135:1962\u20138.","journal-title":"Chin Med J"},{"key":"4126_CR36","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(24)01614-3","volume":"404","author":"PN Taylor","year":"2024","unstructured":"Taylor PN, Medici MM, Hubalewska-Dydejczyk A, Boelaert K. Hypothyroidism. Lancet. 2024;404:1347\u201364.","journal-title":"Lancet"},{"key":"4126_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00059","volume":"10","author":"E Krashin","year":"2019","unstructured":"Krashin E, Piekie\u0142ko-Witkowska A, Ellis M, Ashur-Fabian O. Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies. Front Endocrinol (Lausanne). 2019;10:59.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4126_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20204986","volume":"20","author":"YC Liu","year":"2019","unstructured":"Liu YC, Yeh CT, Lin KH. Molecular functions of thyroid hormone signaling in regulation of cancer progression and anti-apoptosis. Int J Mol Sci. 2019;20:4986.","journal-title":"Int J Mol Sci"},{"key":"4126_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1530\/EJE-17-0197","volume":"177","author":"YX Chan","year":"2017","unstructured":"Chan YX, Knuiman MW, Divitini ML, Brown SJ, Walsh J, Yeap BB. Lower TSH and higher free thyroxine predict incidence of prostate but not breast, colorectal or lung cancer. Eur J Endocrinol. 2017;177:297\u2013308.","journal-title":"Eur J Endocrinol"},{"key":"4126_CR40","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1210\/jc.2013-1607","volume":"98","author":"TH Kim","year":"2013","unstructured":"Kim TH, Kim KW, Ahn HY, Choi HS, Won H, Choi Y, et al. Effect of seasonal changes on the transition between subclinical hypothyroid and euthyroid status. J Clin Endocrinol Metab. 2013;98:3420\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"4126_CR41","doi-asserted-by":"publisher","first-page":"641560","DOI":"10.3389\/fendo.2021.641560","volume":"12","author":"G Effraimidis","year":"2021","unstructured":"Effraimidis G, Watt T, Feldt-Rasmussen U. Levothyroxine therapy in elderly patients with hypothyroidism. Front Endocrinol. 2021;12:641560.","journal-title":"Front Endocrinol"},{"key":"4126_CR42","doi-asserted-by":"publisher","first-page":"e240158","DOI":"10.1530\/ETJ-24-0158","volume":"13","author":"K David","year":"2024","unstructured":"David K, Van Crombrugge P, Van der Biest AM, D\u2019Hondt F, Claessens F, Giesen A, et al. Apalutamide-induced severe hypothyroidism: case series and practice recommendations for thyroid management. Eur Thyroid J. 2024;13:e240158.","journal-title":"Eur Thyroid J"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04126-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04126-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04126-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:03:44Z","timestamp":1767679424000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-025-04126-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4126"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04126-0","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,1]]},"assertion":[{"value":"13 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}